"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note.
Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted.
While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent."
XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov.
With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."
Persons:
Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom
Organizations:
ISI, Biotech, P Biotech, Moderna
Locations:
—